Skip to main content
SpringerLink
Log in

Radioimmunotherapy of Renal Cell Carcinoma

  • Chapter
  • First Online:
Nuclear Medicine Therapy

  • 2042 Accesses

Abstract

There are estimated to be 60,920 new cases of renal carcinoma in the United States in 2011, with an associated annual mortality of 13,120 [1]. On presentation, approximately 70% of renal cortical tumors are confined to the kidney and 30% either present with, or later develop, metastatic disease [2]. The majority of cases (70%) are now discovered incidentally during the course of a cross-sectional imaging procedure obtained for other purposes [3]. The median tumor size is approximately 4 cm, well within safe limits for partial nephrectomy when technically feasible. Recent data demonstrate that 50–70% represent the more aggressive conventional clear cell carcinoma [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society. Cancer facts & figures 2011. Atlanta: American Cancer Society; 2011.

    Google Scholar 

  2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology—Kidney Cancer. Version 2.2011;NCCN.org.

    Google Scholar 

  3. Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol. 2010;7(10):754–73.

    Article  PubMed  Google Scholar 

  4. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163–72.

    Article  PubMed  CAS  Google Scholar 

  5. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell. J Urol. 2001;166:63–7.

    Article  PubMed  CAS  Google Scholar 

  6. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48–51.

    Article  PubMed  Google Scholar 

  7. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol. 2002;20:2376–81.

    Article  PubMed  Google Scholar 

  8. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612–24.

    Article  PubMed  Google Scholar 

  9. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24:5601–8.

    Article  PubMed  CAS  Google Scholar 

  10. Cho DC, Atkins MB. Future directions in renal cell carcinoma: 2011 and beyond. Hematol Oncol Clin North Am. 2011;25(4):917–35.

    Article  PubMed  Google Scholar 

  11. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489–94.

    Article  PubMed  CAS  Google Scholar 

  12. Oosterwijk E, Divgi CR, Brouwers A, et al. Monoclonal antibody-based therapy for renal cell carcinoma. Urol Clin North Am. 2003;30(3):623–31.

    Article  PubMed  Google Scholar 

  13. Brouwers AH, van Eerd JE, Frielink C, et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med. 2004;45:327–37.

    PubMed  CAS  Google Scholar 

  14. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol. 1993;11:738–50.

    PubMed  CAS  Google Scholar 

  15. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4:2729–39.

    PubMed  CAS  Google Scholar 

  16. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 1997;15:1529–37.

    PubMed  CAS  Google Scholar 

  17. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58:75–83.

    Article  PubMed  CAS  Google Scholar 

  18. Divgi CR, O’Donoghue JA, Welt S, et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004;45:1412–21.

    PubMed  CAS  Google Scholar 

  19. Steffens MG, Boerman OC, de Mulder PH, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res. 1999;5(10 Suppl):3268s–74s.

    PubMed  CAS  Google Scholar 

  20. Brouwers AH, Mulders PF, de Mulder PH, et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol. 2005;23:6540–8.

    Article  PubMed  CAS  Google Scholar 

  21. Stillebroer AB, Zegers CM, Boerman OC, et al. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med. 2012;53:82–9.

    Article  PubMed  CAS  Google Scholar 

  22. Welt S, Divgi CR, Real FX, et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol. 1990;8:1894–906.

    PubMed  CAS  Google Scholar 

  23. Loh A, Sgouros G, O’Donoghue JA, et al. Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients. J Nucl Med. 1998;39(3):484–9.

    PubMed  CAS  Google Scholar 

  24. Brouwers AH, Buijs WC, Mulders PF, et al. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res. 2005;11(19 Pt 2):7178s–86s.

    Article  PubMed  CAS  Google Scholar 

  25. Carrasquillo JA, Bunn Jr PA, Keenan AM, et al. Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med. 1986;315:673–80.

    Article  PubMed  CAS  Google Scholar 

  26. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res. 2000;60:4804–11.

    PubMed  CAS  Google Scholar 

  27. Brouwers AH, Buijs WC, Oosterwijk E, et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res. 2003;9(10 Pt 2):3953S–60S.

    PubMed  CAS  Google Scholar 

  28. Oosterwijk-Wakka JC, Kats-Ugurlu G, Leenders WP, et al. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. BJU Int. 2011;107:118–25.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This chapter is dedicated to the memory of Lloyd J. Old, whose seminal observations on the nature and potential of monoclonal antibodies in cancer treatment have influenced the development of cG250 in renal cancer diagnosis and therapy.

Author information

Authors and Affiliations

  1. Department of Radiology, PET/Nuclear Medicine Division Columbia University, 722 W 168 Street R-114, New York, NY, 10032, USA

    Chaitanya Divgi M.D.

Authors
  1. Chaitanya Divgi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chaitanya Divgi M.D. .

Editor information

Editors and Affiliations

  1. Tirocenter Nuclear Medicine Center, Adnan Saygun Cad. 3, Istanbul, 34340, Turkey

    Cumali Aktolun

  2. & Molecular Imaging, New York-Presbyterian Hospital, Division of Nuclear Medicine, East 68th Street 525, New York, 10065, New York, USA

    Stanley J. Goldsmith

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Divgi, C. (2013). Radioimmunotherapy of Renal Cell Carcinoma. In: Aktolun, C., Goldsmith, S. (eds) Nuclear Medicine Therapy. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4021-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4021-5_15

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-4020-8

  • Online ISBN: 978-1-4614-4021-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation